Physician profile
William C Ta
NPI 1790955300
$5,256.91
in general payments reported to CMS, 2019-2025
28 companies · $2,056 in 2025
The $2,056 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $370 · 2021: $332 · 2022: $425 · 2023: $516 · 2024: $1,387 · 2025: $2,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,176.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $808.90 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $565.24 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $533.20 | 2024-2025 | |
| Abbvie INC. | $415.18 | 2023-2025 | Viberzi, Linzess |
| Aimmune Therapeutics, INC. | $212.64 | 2025 | Zenpep |
| Exact Sciences Corporation | $208.24 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Agios Pharmaceuticals, INC. | $201.73 | 2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $182.05 | 2023-2024 | Spravato |
| Vertex Pharmaceuticals Incorporated | $148.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $139.95 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $122.88 | 2019-2023 | |
| Pfizer INC. | $97.43 | 2019-2025 | |
| Ardelyx, INC. | $73.75 | 2025 | Ibsrela |
| Scilex Pharmaceuticals INC. | $54.49 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.59 | 2019 | |
| Xeris Pharmaceuticals, INC. | $38.91 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $35.30 | 2024-2025 | Zoryve |
| Viiv Healthcare Company | $29.89 | 2024 | Apretude |
| Biogen, INC. | $28.72 | 2025 | Spinraza |
| Alfasigma USA, INC. | $20.80 | 2022 | |
| Glaxosmithkline, LLC. | $20.59 | 2019 | |
| Edwards Lifesciences Corporation | $19.56 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $18.64 | 2019 | |
| Qiagen, LLC | $18.63 | 2024 | |
| Phadia US INC. | $16.50 | 2025 | Immunocap |
| Collegium Pharmaceutical, INC. | $15.04 | 2024 | Belbuca |
| Idorsia Pharmaceuticals US INC | $14.21 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.